We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort
- Authors
Gottenberg, Jacques-Eric; Seror, Raphaèle; Miceli-Richard, Corinne; Benessiano, Joelle; Devauchelle-Pensec, Valerie; Dieude, Philippe; Dubost, Jean-Jacques; Fauchais, Anne-Laure; Goeb, Vincent; Hachulla, Eric; Hatron, Pierre Yves; Larroche, Claire; Le Guern, Véronique; Morel, Jacques; Perdriger, Aleth; Puéchal, Xavier; Rist, Stephanie; Saraux, Alain; Sene, Damien; Sibilia, Jean
- Abstract
Objectives: To analyze the clinical and immunological characteristics at enrollment in a large prospective cohort of patients with primary Sjögren's syndrome (pSS) and to investigate the association between serum BAFF, beta2-microglobulin and free light chains of immunoglobulins and systemic disease activity at enrollment. Methods: Three hundred and ninety five patients with pSS according to American-European Consensus Criteria were included from fifteen centers of Rheumatology and Internal Medicine in the “Assessment of Systemic Signs and Evolution of Sjögren's Syndrome” (ASSESS) 5-year prospective cohort. At enrollment, serum markers were assessed as well as activity of the disease measured with the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). Results: Patient median age was 58 (25th–75th: 51–67) and median disease duration was 5 (2–9) years. Median ESSDAI at enrollment was 2 (0–7) with 30.9% of patients having features of systemic involvement. Patients with elevated BAFF, beta2-microglobulin and kappa, lambda FLCS had higher ESSDAI scores at enrollment (4 [2]–[11] vs 2 [0–7], P = 0.03; 4 [1]–[11] vs 2 [0–7], P< 0.0001); 4 [2]–[10] vs 2 [0–6.6], P< 0.0001 and 4 [2–8.2] vs 2 [0–7.0], P = 0.02, respectively). In multivariate analysis, increased beta2-microglobulin, kappa and lambda FLCs were associated with a higher ESSDAI score. Median BAFF and beta2-microglobulin were higher in the 16 patients with history of lymphoma (1173.3(873.1–3665.5) vs 898.9 (715.9–1187.2) pg/ml, P = 0.01 and 2.6 (2.2–2.9) vs 2.1 (1.8–2.6) mg/l, P = 0.04, respectively). Conclusion: In pSS, higher levels of beta2-microglobulin and free light chains of immunoglobulins are associated with increased systemic disease activity.
- Subjects
SJOGREN'S syndrome; SERUM; BETA 2-microglobulin; PRIMARY care; CLINICAL trials; IMMUNOGLOBULINS; RHEUMATOLOGY; CELLULAR immunity; PATIENTS
- Publication
PLoS ONE, 2013, Vol 8, Issue 5, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0059868